Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2025-04-29 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL
Foreign Filer Report
2025-04-29 English
UPDATE ON CAPITELLO-280 PHASE III TRIAL
Foreign Filer Report
2025-04-29 English
1ST QUARTER RESULTS
Foreign Filer Report
2025-04-29 English
Fixed-duration Calquence recommended in EU for CLL
Earnings Release Classification · 1% confidence The document begins with 'RNS Number : 4900G' and is distributed via 'RNS, the news service of the London Stock Exchange.' This strongly indicates a regulatory news service announcement. The content details a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding AstraZeneca's drug Calquence, based on Phase III trial results. This is a significant corporate event announcement related to regulatory/drug approval status. Since it is a general regulatory announcement distributed via RNS and does not fit neatly into specific categories like Earnings Release (ER), Interim Report (IR), or a specific legal/capital event, the most appropriate classification is the general regulatory filing/announcement category, RNS. Q4 2024
2025-04-29 English
Update on CAPItello-280 Phase III trial
Legal Proceedings Report Classification · 1% confidence The document is identified by the 'RNS Number' header and contains a date stamp typical of regulatory news services. The content describes a clinical trial update (discontinuation of CAPItello-280 Phase III trial for Truqap) and includes extensive background information on prostate cancer and the drug mechanism. This type of material, which is a specific corporate announcement disseminated via a regulatory news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). While it is a specific update, RNS serves as the appropriate catch-all for non-standard, time-sensitive regulatory disclosures not covered by the other specific codes.
2025-04-29 English
1st Quarter Results
Earnings Release Classification · 1% confidence The document is an official 'Earnings Release' (ER) for AstraZeneca PLC for the first quarter of 2025. It contains key financial highlights, revenue and EPS summaries, management commentary from the CEO, guidance for the fiscal year, and details on recent M&A and pipeline developments. It is not a full Annual Report (10-K) or a transcript of a call (CT), but rather the initial announcement of quarterly financial results. Q1 2025
2025-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.